STRATA SKIN SCIENCES INC

STRATA Skin Sciences shares plunged 60.8% in premarket trading after the Nasdaq Capital Market announced the delisting. The reason is failure to meet the required shareholder equity threshold of $2.5 million, which was not achieved despite an extension of the deadline to February 16, 2026. Trading in the common shares will be suspended at the opening of trading on February 19, 2026; STRATA will not appeal the decision and plans a “Go Dark” process with an expected SEC filing around March 2, 2026. The company was unable to secure financing on acceptable terms because it would have caused significant dilution; the board sees the removal of listing costs as a benefit for operational focus but acknowledges increased illiquidity of the stock. » Más en de.investing.com

STRATA Skin Sciences reported a 20% revenue decline to $6.9 million in the third quarter of 2025 and a net loss of $1.6 million, with device sales plunging 60%. Adjusted EBITDA was slightly positive and global recurring revenue rose 3%. The company raised $2.2 million via a direct placement, and the stock fell 8.93% in after-hours trading to about $1.62. STRATA expects a stronger fourth quarter, plans 200 TheraClearX installations by year-end and is relying on higher reimbursement rates as a growth driver. » Más en de.investing.com

A U.S. district court ruled partially in favor of STRATA Skin Sciences and barred LaserOptek and The Pinnacle Health Group from marketing in the U.S. in a way that implies reimbursement under certain CPT codes or from making misleading statements about STRATA’s excimer laser. Since the ruling, more than 20 former LaserOptek customers have switched to STRATA’s XTRAC system, representing annualized incremental revenue of over $1.0 million. STRATA recently reported a registered direct offering raising about $2.42 million and filed a prospectus supplement for an at-the-market offering of up to $11 million, while the company continues to face high cash-burn risks and lack of profitability. NASDAQ granted STRATA an extension until February 2026 to meet the minimum listing equity requirement; the company also highlights expanded clinical indications for its XTRAC excimer laser. » Más en de.investing.com